ADC Resistance in Bladder Cancer
Bladder Cancer
ResearchActive
Key Facts
About Elucidate Bio
Elucidate Bio is a private, early-stage biotech services company founded in 2020 and based in San Diego. It operates at the intersection of spatial biology, multi-omics, and artificial intelligence, offering a contract research service to pharmaceutical and biotech companies. The company's core value proposition is using its proprietary methods for same-tissue, multi-modal imaging and AI-driven analysis to uncover predictive biomarkers of patient response, thereby de-risking and accelerating drug development programs. It appears to be pre-revenue or in early revenue, focusing on building its client base and scientific credibility through case studies and partnerships.
View full company profileTherapeutic Areas
Other Bladder Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Platin-DRP® | Chosa Oncology | Development |
| PanGIA Bladder | PanGIA Biotech | Pre-clinical |
| Intravesical IL-2 | Immunservice | Pre-clinical |
| FGFR3 | Onco3R Therapeutics | Phase 1/2 |
| Urine-based Bladder Cancer Detection | Qurin Diagnostics | Pre-clinical |